Brief: Radiopharm Theranostics Announces 50% Enrollment In Phase 2B Clinical Trial Of Rad101 Imaging In Brain Metastases
17/11/2025 13:11
Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS ANNOUNCES 50% ENROLLMENT IN PHASE 2B CLINICAL TRIAL OF RAD101 IMAGING IN BRAIN METASTASES RADIOPHARM THERANOSTICS LTD - PHASE 2B TRIAL TO COMPLETE ENROLLMENT AND HAVE TOPLINE DATA IN 1H26 Source text: ID:nGNX2bPzpf Further company coverage: RAD.AX
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM